CSHL Menu
Lloyd Trotman

Lloyd Trotman

Professor
Cancer Center Deputy Director of Education and Diversity

Ph.D., University of Zurich, 2001

trotman@cshl.edu | (16-367-5054

Trotman Lab Website   Faculty Profile

We have recently developed the first genetic mouse model for therapy and analysis of metastatic prostate cancer. Now we can test if and how modern concepts of cancer evolution can outperform the 80-year-old standard of care- hormone deprivation therapy-and turn lethal prostate cancer into a curable disease.

Lloyd Trotman’s recent research path begins at his discovery some years ago that the loss of a single copy of a master tumor suppressing gene called PTEN is sufficient to permit tumors to develop in animal models of prostate cancer. His team later found that complete loss of PTEN paradoxically triggers senescence, an arrested state that delays or blocks cancer development in affected cells. These findings explained why many patients only display partial loss of this tumor suppressor when diagnosed with prostate cancer. Now the team is researching ways to restore the PTEN protein levels in these patients. This therapeutic approach could slow disease progression and thus greatly reduce the need for surgical removal of the prostate or similar drastic interventions that carry the risks of incontinence and impotence. Their second approach to combat prostate cancer is to model the lethal metastatic disease in genetically engineered mice. They are developing a novel approach that allows for quick generation and visualization of metastatic disease. The efficacy of existing and novel late-stage therapies, such as antihormonal therapy, can then be tested and optimized in these animals. At the same time, the Trotman lab is exploring the genome alterations associated with metastatic disease and with resistance to therapy. To this end, they use single- and multicell genome sequencing techniques developed at CSHL by Drs. Wigler and Hicks.

Pershing Square Sohn Prize

See all Trotman news

All Publications

Combined whole-organ imaging at single-cell resolution and immunohistochemical analysis of prostate cancer and its liver and brain metastases.

16 Nov 2021 | Cell Reports | 37(7):110027
Taranda, Julian, Mathew, Grinu, Watrud, Kaitlin, El-Amine, Nour, Lee, Matthew, Elowsky, Corey, Bludova, Anastasiia, Escobar Avelar, Sintia, Nowak, Dawid, Wee, Tse-Luen, Wilkinson, John, Trotman, Lloyd, Osten, Pavel

Advances in preclinical evaluation of experimental antibody-drug conjugates.

4 Jul 2021 | Cancer Drug Resistance | 4:745-754
Lyons, Scott, Plenker, Dennis, Trotman, Lloyd

SOAT1 promotes mevalonate pathway dependency in pancreatic cancer

7 Sep 2020 | Journal of Experimental Medicine | 217(9)
Oni, T, Biffi, G, Baker, L, Hao, Y, Tonelli, C, Somerville, T, Deschênes, A, Belleau, P, Hwang, C, Sánchez-Rivera, F, Cox, H, Brosnan, E, Doshi, A, Lumia, R, Khaledi, K, Park, Y, Trotman, L, Lowe, S, Krasnitz, A, Vakoc, C, Tuveson, D

Competence against insufficiency: Why are men mostly safe from a rare and deadly prostate cancer?

Jun 2020 | Journal of Experimental Medicine | 217(6):e20200087
Mathew, G, Trotman, L

Roadmap for the Emerging Field of Cancer Neuroscience

16 Apr 2020 | Cell | 181(2):219-222
Monje, M, Borniger, J, D'Silva, N, Deneen, B, Dirks, P, Fattahi, F, Frenette, P, Garzia, L, Gutmann, D, Hanahan, D, Hervey-Jumper, S, Hondermarck, H, Hurov, J, Kepecs, A, Knox, S, Lloyd, A, Magnon, C, Saloman, J, Segal, R, Sloan, E, Sun, X, Taylor, M, Tracey, K, Trotman, L, Tuveson, D, Wang, T, White, R, Winkler, F

PTEN: Bridging Endocytosis and Signaling

9 Dec 2019 | Cold Spring Harbor Perspectives in Medicine
Lee, M, Trotman, L

Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth

29 Oct 2019 | The Prostate
Carbonetti, G, Converso, C, Clement, T, Wang, C, Trotman, L, Ojima, I, Kaczocha, M

Bioactivation of napabucasin triggers reactive oxygen species-mediated cancer cell death

16 Sep 2019 | Clinical Cancer Research | 25(23):7162-7174
Froeling, F, Mosur Swamynathan, M, Deschenes, A, Chio, I, Brosnan, E, Yao, M, Alagesan, P, Lucito, M, Li, J, Chang, A, Trotman, L, Belleau, P, Park, Y, Rogoff, H, Watson, J, Tuveson, D

Combined inhibition of tumor suppressors PTEN and PP2A drives anoikis resistance and is associated with therapy relapse in prostate cancer

Jul 2019 | Cancer Research | 79(13S):Meeting Abstract: 3486
Rupp, C, Isomursu, A, Aakula, A, Erickson, A, Li, S, Kaur, A, Shah, P, Pokharel, Y, Trottman, L, Lammerding, J, Rannikko, A, Taimen, P, Mirtti, T, Paatero, I, Ivaska, J, Westermarck, J

The PHLPP2 phosphatase is a druggable driver of prostate cancer progression

15 May 2019 | The Journal of Cell Biology | 218(6):1943-1957
Nowak, D, Katsenelson, K, Watrud, K, Chen, M, Mathew, G, D'Andrea, V, Lee, M, Swamynathan, M, Casanova-Salas, I, Jibilian, M, Buckholtz, C, Ambrico, A, Pan, C, Wilkinson, J, Newton, A, Trotman, L

See more publications